Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. In the meantime, a search for Jørgensen’s successor is ongoing. Novo Nordisk says the leadership transition is “made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s share price since mid-2024.” Considering the recent market challenges, the share price decline, and wishes from the Novo Nordisk Foundation, the Novo Nordisk Board and Jørgensen have jointly...